Reserpine administered via the oral route is rapidly absorbed, reaching its peak concentration level after approximately 2 hours. Reserpine has a bioavailability of approximately 50%Â to 70% and an elimination half-life of 11.5 days. Administering reserpine beyond the upper dosage limit can lead to central nervous system depression, bradycardia, hypotension, lethargy, and coma. Reserpine is assigned Pregnancy Category C.

There are currently no recommended routine tests or laboratory analyses for monitoring the use of reserpine.